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Heparin-induced thrombocytopenia syndrome is an acquired potentially life-threatening prothrombotic
disorder caused by antibodies that recognize complexes of platelet factor 4 bound to heparin or heparin-
like molecules. It typically occurs after exposure to unfractionated heparin, to a lesser extent after
exposure to low-molecular-weight heparins, and rarely after exposure to fondaparinux. Herein, we
report the case of a 48-year-old woman who developed severe thrombocytopenia, bilateral pulmonary
embolism, and bilateral adrenal hemorrhages after total knee arthroplasty without evidence of heparin
exposure. Antibodies to the heparin-platelet factor 4 complex and serotonin-release assay were positive.
Spontaneous heparin-induced thrombocytopenia syndrome should be considered in patients with un-
explained thrombocytopenia after knee replacement surgery even without heparin exposure, and a high
index of suspicion for adrenal hemorrhage is needed in patients with fever, abdominal pain, and shock.
Copyright © 2015 Published by Elsevier Inc. on behalf of American Association of Hip and Knee Surgeons.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Heparin-induced thrombocytopenia (HIT) is an acquired,
potentially life-threatening, prothrombotic disorder caused by an-
tibodies that recognize complexes of platelet factor 4 (PF4) bound
to heparin or heparin-like molecules [1]. It typically occurs after
exposure to unfractionated heparin, to a lesser extent after expo-
sure to low-molecular-weight heparin (LMWH), and rarely after
exposure to fondaparinux [2,3]. Although HIT is invariably related
to heparin exposure, few reports described patients who developed
HIT without any history of heparin exposure [4e7]. Herein, we
report the case of a 48-year-old woman who developed severe
thrombocytopenia, bilateral pulmonary embolism (PE), andd any potential or pertinent
conﬂict with this work. For
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, Albany, NY 12208, USA.
c. on behalf of American Associatio
d/4.0/).bilateral adrenal hemorrhages (BAHs) after total knee arthroplasty
(TKA) without evidence of heparin exposure.Case history
A 48-year-old female patient with left knee osteoarthritis un-
derwent primary left TKA (Nex Gen High Flex, Zimmer Inc., War-
saw, IN, USA) uneventfully. She received aspirin postoperatively for
deep venous thrombosis (DVT) prophylaxis. The patient started
continuous passive motion exercise the day after the surgery, and
the drain was removed after putting out an insigniﬁcant amount.
She continued to do well in regards to pain and knee function and
was discharged home on postoperative day (POD) 3. On POD 8, she
was readmitted to the hospital for low-grade fever and abdominal
pain. Her platelet count on admission was 362,000/mL which then
dropped to 187,000/mL on the following day (before any heparin
exposure). She then received LMWH for DVT prophylaxis on the
second day of readmission, and her platelet count dropped further
to 57,000/mL (POD 10).n of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND
Figure 1. Axial CT images demonstrating (a) bilateral adrenal gland enlargements and diffuse hemorrhage (arrows) and (b) bilateral pulmonary emboli.
A. Elshoury et al. / Arthroplasty Today 1 (2015) 69e7170Peripheral blood smear analysis conﬁrmed her thrombocyto-
penia and did not show any evidence of microangiopathic hemo-
lysis. Anticardiolipin antibodies and lupus anticoagulants were not
present. In light of her progressive thrombocytopenia, there was a
concern for HIT. Immunoglobulin Gespeciﬁc PF4-heparin enzyme
immunoassay and the platelet serotoninerelease assay were
strongly positive (100% serotonin release at 0.1 U/mL of heparin and
0% serotonin release at 100 U/mL of heparin). The patient then
developed severe abdominal pain with profound hypotension and
was immediately transferred to the intensive care unit. Computed
tomography (CT) of the abdomen and pelvis showed BAHs (Fig. 1a).
The patient was empirically started on pulse steroids for possible
adrenal insufﬁciency with marked improvement in her vital status.
However, platelet count dropped further to 15,000/mL, and she
developed pleuritic chest pain and becamemore tachypneic, which
raised the suspicion for possible PE. CT pulmonary angiography
showed bilateral PE (Fig. 1b), and therapeutic anticoagulation was
initiated with argatroban, a direct thrombin inhibitor, with a target-
activated partial thromboplastin time (PTT) of 1.5 to 2 times
baseline level. Her platelet count began to increase gradually, but
the anticoagulation was frequently interrupted because of supra-
therapeutic PTT values. The patient then developed recurrent
pleuritic chest pain and tachycardia which raised the concern for
recurrent PE. Repeat CT pulmonary angiography conﬁrmed the
presence of new bilateral PE (Fig. 2) for which an inferior vena cavaFigure 2. Clinical course of a patient with spontaneous HIT presentingﬁlter was placed. She continued anticoagulation with argatroban
and was bridged to warfarin after her platelet count had risen to
over 150,000/mL.
Throughout her hospital readmission, the patient continued
to work with physical therapy. Gradual improvement in the
muscle strength and range of motion (ROM) of the knee was
noted. On discharge, the patient was able to ambulate without
signiﬁcant knee pain. Her ROM was 0 to 100, and the knee
incision was healing without any wound complications. The
patient continued to follow-up and her platelet count
remained normal. She also continued on steroids replacement
therapy for adrenal insufﬁciency after she failed multiple
weaning trials. At 1-year postoperative, the knee wound was
completely healed. The patient was ambulating without any
assisted devices, and she had 0 to 120 of active ROM without
any pain. Follow-up radiographs showed maintained align-
ment of the prosthesis without any signs of loosening or
instability.
Discussion
We described a rare case of life-threatening spontaneous HIT
after TKA, presenting as BAHs (indicating bilateral adrenal vein
thrombosis) and bilateral PE, triggered by administration of LMWH
without any previous heparin exposure. Our patient received 325-as bilateral adrenal hemorrhage and bilateral pulmonary emboli.
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review of the patient's preoperative and postoperative medication
history did not show any evidence of heparin exposure (no hepa-
rinized devices or heparin ﬂushes). The only exposure to heparin
was during her second hospitalization where she received 1 time
prophylactic LMWH. Of note, her platelet count already repre-
sented a 50% drop from the admission platelet count even before
she received the LMWH.
Although HIT is invariably triggered by preceding heparin
exposure, there are few case reports describing patients with
clinical and serologic features of HIT despite the absence of previ-
ous heparin exposure [7,8]. Our patient had knee arthroplasty 8
days before the onset of thrombocytopenia. Heparin-like mole-
cules, such as glycosaminoglycans can be released during knee
replacement surgery triggering the generation of anti-PF4/heparin
complexes [9,10]. Thus, it is possible that our patient had preex-
isting anti-PF4/Heparin antibodies before any heparin exposure,
resulting from the knee surgery, and on LMWH exposure, therewas
a rapid drop in her platelet count.
Our patient also developed recurrent PE because of frequent
interruption of the argatroban dosing in the setting of supra-
therapeutic PTT. PTT is used to monitor argatroban dosing but can
be confounded by the severe HIT itself or by the associated
comorbidities [11]. Supratherapeutic PTT, however, does not
necessarily indicate a supratherapeutic drug level, which is
considered a drawback of using direct thrombin inhibitor therapy
in treating HIT.
Future surgeries can be a challenge in patients with history of
HIT because they are at a theoretical increased risk of rapid-onset
HIT. Current American College of Chest Physicians guidelines
recommend against heparin reexposure in patients with a history
of HIT [12]. Nevertheless, heparin can still be used, for short term
only, in patients who require cardiac surgery provided that repeat
PF4/heparin antibodies are negative. DVT prophylaxis can be ach-
ieved with fondaparinux [3,13] in patients with creatinine clear-
ance >30 mL/min or with argatroban in patients with creatinine
clearance <30 mL/min [14].
Summary
In summary, we report a rare case of spontaneous HIT pre-
senting as severe thrombocytopenia, recurrent PE, and BAH after
TKA. Spontaneous HIT should be considered in patients with un-
explained thrombocytopenia after knee replacement surgery evenwithout heparin exposure, and a high index of suspicion for adrenal
hemorrhage is needed in patients with fever, abdominal pain, and
shock.
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